Abitec Corporation, a specialty lipid manufacturer, has expanded its custom synthesis capabilities to include high-purity lipids for lipid nanoparticle (LNP) therapeutics.
 
The comprehensive bench-to-patient service offering will address key market challenges, including limited availability of cGMP-grade lipids and unpredictable lead times. LNP developers in pharma, biotech, and academia will now be able to efficiently overcome their toughest lipid chemistry challenges and drive their LNP therapeutics programs forward.
 
With multiple GMP manufacturing facilities, an established global footprint, and a dedicated team of PhD chemists and scientists experienced in LNP therapy applications, Abitec can now reliably deliver ultra-pure custom lipids from mg to kg scale, all from a single partner.
 
Jeff Walton, CEO of Abitec, said, “This launch significantly expands Abitec’s functional lipids manufacturing capabilities to include custom lipid synthesis for the formulations of LNPs and other highly functional drug delivery platforms and technologies. Abitec customers can now access research-grade and cGMP lipids specifically designed to meet their unique applications requirements. We look forward to continually supporting our customers with advanced technologies to help overcome complex challenges and enable enhanced therapeutic outcomes.”